Design of an optimized scaffold for affibody molecules.

Affibody molecules are non-immunoglobulin-derived affinity proteins based on a three-helical bundle protein domain. Here, we describe the design process of an optimized Affibody molecule scaffold with improved properties and a surface distinctly different from that of the parental scaffold. The improvement was achieved by applying an iterative process of amino acid substitutions in the context of the human epidermal growth factor receptor 2 (HER2)-specific Affibody molecule Z(HER2:342). Replacements in the N-terminal region, loop 1, helix 2 and helix 3 were guided by extensive structural modeling using the available structures of the parent Z domain and Affibody molecules. The effect of several single substitutions was analyzed followed by combination of up to 11 different substitutions. The two amino acid substitutions N23T and S33K accounted for the most dramatic improvements, including increased thermal stability with elevated melting temperatures of up to +12 degrees C. The optimized scaffold contains 11 amino acid substitutions in the nonbinding surface and is characterized by improved thermal and chemical stability, as well as increased hydrophilicity, and enables generation of identical Affibody molecules both by chemical peptide synthesis and by recombinant bacterial expression. A HER2-specific Affibody tracer, [MMA-DOTA-Cys61]-Z(HER2:2891)-Cys (ABY-025), was produced by conjugating MMA-DOTA (maleimide-monoamide-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to the peptide produced either chemically or in Escherichia coli. ABY-025 showed high affinity and specificity for HER2 (equilibrium dissociation constant, K(D), of 76 pM) and detected HER2 in tissue sections of SKOV-3 xenograft and human breast tumors. The HER2-binding capacity was fully retained after three cycles of heating to 90 degrees C followed by cooling to room temperature. Furthermore, the binding surfaces of five Affibody molecules targeting other proteins (tumor necrosis factor alpha, insulin, Taq polymerase, epidermal growth factor receptor or platelet-derived growth factor receptor beta) were grafted onto the optimized scaffold, resulting in molecules with improved thermal stability and a more hydrophilic nonbinding surface.

[1]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[2]  L Serrano,et al.  Elucidating the folding problem of alpha-helices: local motifs, long-range electrostatics, ionic-strength dependence and prediction of NMR parameters. , 1998, Journal of molecular biology.

[3]  W. Chan,et al.  Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series) , 2019 .

[4]  J. Deisenhofer.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[5]  Fredrik Y Frejd,et al.  Generation of tumour‐necrosis‐factor‐α‐specific affibody 1 molecules capable of blocking receptor binding in vitro , 2009, Biotechnology and applied biochemistry.

[6]  James M Aramini,et al.  Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data , 2004, Protein science : a publication of the Protein Society.

[7]  J. Feldwisch,et al.  Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. , 2008, Bioconjugate chemistry.

[8]  M. Uhlén,et al.  A combinatorial library of an α-helical bacterial receptor domain , 1995 .

[9]  John Orban,et al.  NMR structures of two designed proteins with high sequence identity but different fold and function , 2008, Proceedings of the National Academy of Sciences.

[10]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[11]  L. Martiniova,et al.  [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Vladimir Tolmachev,et al.  Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.

[13]  S. Mather,et al.  99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. , 1999, Nuclear medicine and biology.

[14]  G. Adams,et al.  In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. , 2005, Cancer biotherapy & radiopharmaceuticals.

[15]  V. Chernomordik,et al.  Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging , 2008, Clinical Cancer Research.

[16]  B. Jansson,et al.  The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab')2: separation of affinity from specificity. , 1993, Molecular immunology.

[17]  H. Berglund,et al.  An affibody in complex with a target protein: Structure and coupled folding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  I. Shimada,et al.  Three-dimensional solution structure of the B domain of staphylococcal protein A: comparisons of the solution and crystal structures. , 1992, Biochemistry.

[19]  Jakob Dogan,et al.  Structural basis for molecular recognition in an affibody:affibody complex. , 2006, Journal of molecular biology.

[20]  E. Lundberg,et al.  Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. , 2007, Journal of immunological methods.

[21]  Caroline Kampf,et al.  Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. , 2003, Journal of immunological methods.

[22]  S. Lindström,et al.  Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides , 2007 .

[23]  Torbjörn Gräslund,et al.  Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach , 2004, Proteins.

[24]  Richard A Goldstein,et al.  Why are proteins so robust to site mutations? , 2002, Journal of molecular biology.

[25]  V. Daggett,et al.  Staphylococcal protein A: unfolding pathways, unfolded states, and differences between the B and E domains. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Tolmachev.  Imaging of HER-2 overexpression in tumors for guiding therapy. , 2008, Current pharmaceutical design.

[27]  G T Montelione,et al.  High-resolution solution NMR structure of the Z domain of staphylococcal protein A. , 1997, Journal of molecular biology.

[28]  I. Lyakhov,et al.  Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors , 2009, Journal of immunotherapy.

[29]  S. Gambhir,et al.  Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules , 2008, Journal of Nuclear Medicine.

[30]  S. Hober,et al.  Protein A chromatography for antibody purification. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  Stefan Ståhl,et al.  Engineered affinity proteins--generation and applications. , 2009, Journal of biotechnology.

[32]  J. Carlsson,et al.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.

[33]  M. Uhlén,et al.  All individual domains of staphylococcal protein A show Fab binding. , 2006, FEMS immunology and medical microbiology.

[34]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[35]  John Löfblom,et al.  A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. , 2008, Protein engineering, design & selection : PEDS.

[36]  G. Adams,et al.  Selection and characterization of HER2/neu-binding affibody ligands. , 2004, Protein engineering, design & selection : PEDS.

[37]  M. Mutter,et al.  SERINE DERIVED OXAZOLIDINES AS SECONDARY STRUCTURE DISRUPTING, SOLUBILIZING BUILDING-BLOCKS IN PEPTIDE-SYNTHESIS , 1992 .

[38]  M. Taussig,et al.  Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Jakob Dogan,et al.  Biophysical characterization of ZSPA‐1—A phage‐display selected binder to protein A , 2004, Protein science : a publication of the Protein Society.

[40]  J. Ruczyński,et al.  Problem of aspartimide formation in Fmoc‐based solid‐phase peptide synthesis using Dmab group to protect side chain of aspartic acid , 2008, Journal of peptide science : an official publication of the European Peptide Society.

[41]  E. Sasso,et al.  Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. , 1991, Journal of immunology.

[42]  P. Nordlund,et al.  Structural basis for recognition by an in vitro evolved affibody , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Oas,et al.  Fast and faster: A designed variant of the B‐domain of protein A folds in 3 μsec , 2004 .

[44]  Fredrik Y Frejd,et al.  Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule , 2009, Biotechnology and applied biochemistry.

[45]  E. Johansson,et al.  Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. , 2008, Journal of molecular biology.

[46]  M. Uhlén,et al.  A synthetic IgG-binding domain based on staphylococcal protein A. , 1987, Protein engineering.

[47]  H. Scheraga,et al.  An atomically detailed study of the folding pathways of protein A with the stochastic difference equation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Dyson,et al.  Absence of a stable intermediate on the folding pathway of protein A , 1997, Protein science : a publication of the Protein Society.

[49]  H. Brismar,et al.  Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. , 2007, Protein engineering, design & selection : PEDS.

[50]  F. Studier,et al.  Use of T7 RNA polymerase to direct expression of cloned genes. , 1990, Methods in enzymology.

[51]  R. Pehrson,et al.  Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.

[52]  H. Brumer,et al.  Chemical Synthesis of Triple‐Labelled Three‐Helix Bundle Binding Proteins for Specific Fluorescent Detection of Unlabelled Protein , 2005, Chembiochem : a European journal of chemical biology.

[53]  M. Uhlén,et al.  Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. , 2002, Journal of immunological methods.